a Department of Medical Genetics , Women's Reproductive Health Research Center , Tabriz , Iran.
b Student Research Committee , Tabriz University of Medical Sciences , Tabriz , Iran.
Artif Cells Nanomed Biotechnol. 2018;46(sup2):241-247. doi: 10.1080/21691401.2018.1454931. Epub 2018 Mar 23.
MicroRNAs (miRNAs) have had a revolutionary impact on cancer research over the recent years. They emerge as important players in tumourigenesis, leading to a paradigm shift in oncology. Ovarian cancer is the leading cause of death among gynaecologic malignancies. Therefore, there is a strong need for prognostic and predictive markers for early diagnosis which helps optimize and personalize treatment. Asymptomatically, ovarian cancer is often diagnosed at advanced and incurable stages. Efficient targeting and sustained release of miRNAs/anti-miRNAs using nanoparticles conjugated with antibodies and/or peptides could reduce the required therapeutic dosage while minimizing systemic and cellular toxicity. Given miRNAs importance in clinical oncology, here we focus on the development of miRNA nanoformulations to achieve enhanced cellular uptake, bioavailability and accumulation at the tumour site. Although many obstacles need to be overcome, miRNA therapy could be a powerful tool for ovarian cancer prevention and treatment. In this review, we discuss about the emerging roles of miRNAs in various aspects of ovarian cancer.
近年来，微小 RNA（miRNAs）在癌症研究中产生了革命性的影响。它们作为肿瘤发生的重要参与者出现，导致肿瘤学发生范式转变。卵巢癌是妇科恶性肿瘤死亡的主要原因。因此，迫切需要用于早期诊断的预后和预测标志物，以帮助优化和个性化治疗。卵巢癌通常在无症状时被诊断为晚期和不可治愈的阶段。使用与抗体和/或肽偶联的纳米粒子来有效靶向和持续释放 miRNAs/抗 miRNAs，可以减少所需的治疗剂量，同时最大限度地减少全身和细胞毒性。鉴于 miRNAs 在临床肿瘤学中的重要性，我们在此重点介绍 miRNA 纳米制剂的开发，以实现增强的细胞摄取、生物利用度和在肿瘤部位的积累。尽管需要克服许多障碍，但 miRNA 疗法可能是预防和治疗卵巢癌的有力工具。在这篇综述中，我们讨论了 miRNAs 在卵巢癌各个方面的新兴作用。
